Credits Available: 4.75 AMA PRA Category 1 Credit™/ MOC Points

Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HR+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant, Nurse, Pharmacist, Respiratory Therapist
Target Specialties: Oncology, Hematology/Oncology

Jad Abdelsattar

University of Arizona
Clinical Assistant Professor, Surgery

Jad M Abdelsattar, MD, is a Board Certified and Fellowship trained Breast Surgical Oncologist and serves as a Clinical Assistant Professor of Surgery in the Division of Surgical Oncology at the University of Arizona College of Medicine -Tucson Department of Surgery.

He specializes in breast cancer surgery and offers his patients breast conserving surgery when applicable. Dr. Abdelsattar completed his fellowship training in Breast Surgical Oncology and Oncoplasty at the University of Southern California-Hoag fellowship program, and is board certified by the American Board of Surgery.